Cargando…
Possible Repositioning of an Oral Anti-Osteoporotic Drug, Ipriflavone, for Treatment of Inflammatory Arthritis via Inhibitory Activity of KIAA1199, a Novel Potent Hyaluronidase
KIAA1199 has a strong hyaluronidase activity in inflammatory arthritis. This study aimed to identify a drug that could reduce KIAA1199 activity and clarify its effects on inflammatory arthritis. Rat chondrosarcoma (RCS) cells were strongly stained with Alcian blue (AB). Its stainability was reduced...
Autores principales: | Koike, Hiroshi, Nishida, Yoshihiro, Shinomura, Tamayuki, Ohkawara, Bisei, Ohno, Kinji, Zhuo, Lisheng, Kimata, Koji, Ushida, Takahiro, Imagama, Shiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030858/ https://www.ncbi.nlm.nih.gov/pubmed/35456905 http://dx.doi.org/10.3390/ijms23084089 |
Ejemplares similares
-
Development of Therapeutic Agent for Osteoarthritis via Inhibition of KIAA1199 Activity: Effect of Ipriflavone In Vivo
por: Zhang, Jiarui, et al.
Publicado: (2023) -
Overexpression of KIAA1199, a novel strong hyaluronidase, is a poor prognostic factor in patients with osteosarcoma
por: Ito, Kan, et al.
Publicado: (2021) -
Repositioning again of zonisamide for nerve regeneration
por: Ohno, Kinji, et al.
Publicado: (2016) -
KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer
por: Kohi, Shiro, et al.
Publicado: (2017) -
Human TMEM2 is not a catalytic hyaluronidase, but a regulator of hyaluronan metabolism via HYBID (KIAA1199/CEMIP) and HAS2 expression
por: Sato, Shinya, et al.
Publicado: (2023)